SCHEMBL18281167

SCHEMBL18281167

Cc1ccc2c(c1)cc(C(=O)O)c1cc(C)ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.50
HSD17B10 Q99714 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
MAOB P27338 1/20 0.50
CA5A P35218 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
CSNK2A1 P68400 1/20 0.48
LDHA P00338 2/20 0.45
LDHB P07195 2/20 0.45
MPL P40238 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18281149 0.88 MEN1 (0.58) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL13057666 0.81 MEN1 (0.49) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL9476237 0.80 RXFP1 (0.57) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL5833643 0.80 CSNK2A1 (0.55) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL24895105 0.80 CSNK2A1 (0.52) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL19202294 0.80 CSNK2A1 (0.52) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL931067 0.79 LDHA (0.50) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL6347777 0.79 MEN1 (0.50) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL3628515 0.79 LDHA (0.50) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL13057645 0.79 LDHA (0.54) MEN1KMT2AALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11029303-B2 PAH antibodies and uses thereof THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2021-06-08 US disclosed
WO-2016196638-A2 PAH ANTIBODIES AND USES THEREOF THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11029303-B2 PAH antibodies and uses thereof PAH, AHR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MEN1 1080/4885KMT2A 726/4885ALDH1A1 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.